Matt McNamara
Managing Director @ BioScience Managers Limited
Melbourne, Australia
Matt McNamara is a Series D investor at BioScience Managers Limited in Melbourne focused on Health Care and Medical Device. Matt is responsible for deal flow management and evaluation, leading all investment recommendations and due diligence. He reports to the Managing Director. He has over 23 years experience in the healthcare & medical sciences sector. After initially being a Molecular Biology Research Assistant, Matt spent 11 years in Sales & Marketing, andGeneral Management with Merck & Co. and Johnson and Johnson Medical Pty. Ltd. respectively. He has served as SVP Business Development for a University of Sydney spin out, eBioinformatics Inc. and was CEO of a Life Sciences Venture Capital fund, SciCapital Pty. Ltd.Matt founded BioBridge Australia, a biotechnology Commercialisation Advisory company, in 2004 and advised a number of private and public biotechnology/investment companies. He is a Director of SciCapital Pty Ltd a private biotech investment company. Since 2008, Matt has been Chief Investment Officer of Bioscience Managers Pty Ltd.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Matt McNamara invests in
Stages Matt McNamara invests in
Countries Matt McNamara invests in
Investment Focus
Industry
- Health Care 2 (50%)
- Medical Device 2 (50%)
- Therapeutics 1 (25%)
- Biotechnology 1 (25%)
Stage
- Series D 1 (25%)
- Series E 1 (25%)
- Venture - Series Unknown 1 (25%)
Country
- Switzerland 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Xeltis
|
A clinical-stage medical device company, Xeltis has developed the most advanced polymer-based restorative devices for cardiovascular treatment. Xeltis’ restorative devices include implantable small diameter blood vessels for hemodialysis vascular access and for coronary artery bypass graft (CABG) surgery and pulmonary heart valves, for whichclinical trials are ongoing. Xeltis was formed through the merger of two Dutch/Swiss university spin-offs. It currently has operations in The Netherlands and in the USA. Xeltis’ investors include venture capital funds EQT Life Sciences, Kurma Partners, VI Partners and Ysios Capital as well as a number of private investors. In 2021, Xeltis secured a €15 million financing from the European Investment Bank and a €15 million funding from the European Innovation Council Accelerator (EIC) set up by the European Commission. | $23.3M / Venture - Series Unknown / Jul 28, 2026 | |
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M / Series E / Mar 20, 2025 | |
|
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $53M / Series E / Mar 20, 2025 | |
|
Cardiac Dimensions
|
Cardiac Dimensions, Inc. is a medical device company developing novel interventional tools for the treatment of heart failure and the related condition of mitral valve regurgitation. Our product, the Carillon® Mitral Contour System®, is a groundbreaking, non-surgical device developed to treat functional mitral valve regurgitation. Our system uses acatheter based approach to reshape the mitral valve and reduce mitral regurgitation. | $35M / Series D / Jan 05, 2023 |
Co-Investors
About BioScience Managers Limited
BioScience Managers Pty Ltd (formerly IB Managers) is a leading life sciences investment firm, headquartered in Melbourne, Australia. Established in 2003, BioScience Managers offers a global, multi-disciplinary team, bringing an international perspective together with the track record, networks and expertise required to convert that perspectiveinto informed, high return investment decisions.We operate a high value-add model, providing assistance and support to portfolio companies via our global team and international network of independent industry advisors. With combined experience of over 170 investments, more than 40 IPO’s/ reversals in Europe, the USA and Australia, and a diverse skillset specific to the bio-based industries, we aim to provide investee companies with significant value-add over and above capital invested.Alongside our funds management business, Phillip Bioscience Advisory provides specialist corporate advisory services to healthcare and life sciences companies.
BioScience Managers Limited Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Amanda Gillon
Investment Analyst
|
|||
|
Matt McNamara
Managing Director
|
|||
Nora Frey
Investment Manager
|
|||
Bronwyn Dilley
senior executive
|
|||
Jeremy Curnock Cook
Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Matt McNamara invest in?
Matt McNamara invests primarily in Health Care, Medical Device and Therapeutics startups, most often at Series D and Series E stage. Most of the 4 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Matt McNamara last invest?
The most recent investment recorded for Matt McNamara closed in Jul 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
